Canertinib is a potent and selective inhibitor of tyrosine residue phosphorylation of EGFR, blocking signal transgression and ceasing angiogenisis. Canertinib displays an IC50 = 1.5nM. Additionally, Canertinib's action in inhibiting EGFR increases apoptosis in cancerous cell lines in a titratable fashion.
Li, D., et al.: Oncogene, 27, 4702 (2008), Brown, A., et al.: Toxicol. Pathol., 36, 410 (2008), Chen, H., et al.: Chem. Biol. Drug Design, 71, 434 (2008),
Soluble in DMSO (2 mg/ml), methanol, ethanol (9 mg/ml), and water (<1 mg/ml).
Store at room temperature
~691° C at 760 mmHg (Predicted)
~1.4 g/cm3 (Predicted)
n20D 1.65 (Predicted)
EGFR: IC50 = 1.5 nM; ErbB2: IC50 = 9.0 nM
pKa: 12.09 (Predicted), pKb: 6.99 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn